Metabolite Tales Blog

NOVEMBER 17, 2022

Roquinimex (Linomide), a drug developed by Pfizer for the treatment of multiple sclerosis, is structurally related to laquinimod. Teva Pharmaceuticals licensed laquinimod from Active Biotech. In a 2021 publication, Rothhammer et al. It lacks a chlorine substituent and contains an N- methyl group instead of an N- ethyl group.

International 52

International Licensing Licensing Treatment 52

The Pharma Data

JANUARY 27, 2021

. “The responses observed in six out of nine patients are very encouraging and clearly suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives. CEO of BioInvent. Readout from two patients is still pending.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 26, 2020

AR-711 was previously shown to be effective in prophylactic as well as therapeutic treatment modes in a SARS-CoV-2 viral challenge study. AR-711 is currently being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate COVID-19. About Aridis Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Visiting address: Sölvegatan 41.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

JANUARY 26, 2021

27, 2021 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer’s disease. STOCKHOLM , Jan. SOURCE BioArctic.

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

JANUARY 19, 2021

The event will feature a presentation by renowned lymphoma expert Mats Jerkeman, MD, Lund University, who will discuss the current treatment landscape, and unmet medical need for patients with relapsed or refractory Non-Hodgkin’s Lymphoma for whom current treatment options are very limited. SOURCE BioInvent. Source link.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

DECEMBER 16, 2020

We are entering an area with significant unmet medical need since the current treatment paradigm for GBM remains bleak, as this aggressive and currently incurable form of brain cancer continues to claim high mortality rates. View original content to download multimedia: [link]. . .

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

DECEMBER 15, 2020

This is an important step towards a licensing agreement for Lipidor drug candidates, AKP01 and AKP02, for the treatment of psoriasis. The following files are available for download: View original content: [link]. This will enable Lipidor to offer potential licensees the opportunity for large-scale commercial production.

Production 52

Production Laboratories Licensing Licensing 52

The Pharma Data

OCTOBER 19, 2020

(NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Company’s U.S. View original content to download multimedia: [link].

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Treatment 52

The Pharma Data

JANUARY 31, 2021

This innovative technology harnesses the power of sound for the treatment of cellulite. The unique, rapid-pulsed technology safely and comfortably breaks apart the fibrous septa bands beneath the skin that cause cellulite to deliver efficacious results in just one, 40–60-minute treatment. out of 10. .

FDA 52

FDA Treatment Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 26, 2020

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. SOURCE BioInvent. Source link.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

DECEMBER 29, 2020

Shapiro served as Senior Director of the North America Device Division at Merz, where he successfully led a team of over 60 sales professionals and helped launch Cellfina, a cellulite treatment device which generated $15 million in sales during the first year, along with Ultherapy, an industry leading skin tightening device.

FDA 52

FDA Licensing Licensing Production 52

The Pharma Data

JANUARY 13, 2021

Mr. Barrow has over a decade of experience leading drug development programs aimed at identifying and testing novel treatments in a wide range of disease conditions under FDA and EMA. View original content to download multimedia: [link]. . NEW YORK , Jan. MindMed Co-CEO J.R.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

The Pharma Data

NOVEMBER 10, 2020

. The poster presentation, given by Johan Sandin , CSO at AlzeCure, presents how the mechanisms in the research platform Alzstatin work and shows that the target mechanism within the platform is suitable as a new treatment for Alzheimer’s disease. About AlzeCure Pharma AB (publ).

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

The Pharma Data

JANUARY 10, 2021

Food and Drug Administration (FDA) around a proposed study protocol for a new, randomized controlled study of imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients. Imlifidase as pre-treatment ahead of gene therapy in DMD and LGMD. Pre-clinical programs. .

Therapies 40

Therapies Treatment Trials Disease 40

The Pharma Data

JANUARY 18, 2021

a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases, today announced its launch backed by $80 million Series C financing led by Abingworth LLP. Therefore, atacicept may be uniquely positioned to be disease-modifying for these patients with no current treatment options.”

Disease 40

Disease Science Clinical Development Treatment 40

The Pharma Data

NOVEMBER 2, 2020

for the Treatment of Achondroplasia. This acceptance by the FDA marks the first marketing application accepted for a treatment for achondroplasia in the United States. The study will be followed by a subsequent open-label extension trial when all subjects receive active treatment. If approved, 1st Therapy in U.S.

Drugs 40

Drugs FDA Treatment Pharmaceuticals 40

PPD

JULY 9, 2024

At present, we have 99% first-cycle approvals, 100% licenses obtained, 100% dossiers validated and over 99% of submission milestones achieved on behalf of our clients. Download our white paper The post FSP Flex Hub Teams Maximize Efficiency Across Lifecycle Maintenance appeared first on PPD. Let’s connect.

Compliance 52

Compliance Production Clinical Research Marketing 52

The Pharma Data

NOVEMBER 4, 2020

CTP-543: An Investigational Treatment for Moderate to Severe Alopecia Areata. The presentation highlighted that in the open label extension study, treatment with CTP-543 shows continued maintenance of hair regrowth relative to the hair growth shown in the Company’s previously conducted Phase 2 trials in patients with alopecia areata.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Treatment 52

Advarra

JULY 19, 2022

Q: If an emergency use authorization (EUA) is granted, once there is an approved treatment, does that mean that the EUA is no longer valid? For more information on key components of a fit-for-purpose, phase-by-phase QMS guidance download Advarra’s whitepaper Steps to Implementing a Quality Management System.

Packaging 52

Packaging FDA Trials Regulations 52

The Pharma Data

NOVEMBER 9, 2020

NAVIGATOR is a Phase 3, randomized, double-blinded, placebo-controlled trial in adults (18–80 years old) and adolescents (12–17 years old) with severe, uncontrolled asthma, who were receiving treatment with medium- or high-dose ICS plus at least one additional controller medication with or without OCS. Severe Asthma in Adults.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

SEPTEMBER 16, 2020

Eligible patients were heavily pretreated with at least two or more prior lines of treatment, consistent with their tumor type and stage of disease. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T cell treatment available to all providers when their patients need it.

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

SEPTEMBER 20, 2020

No dose-limiting toxicities were observed and there were no fatal treatment-related adverse events (TRAEs). Eleven (18.6%) patients had grade 3 or higher TRAEs, one of whom had grade 3 TRAEs of ALT and AST increases that led to discontinuation of treatment. ” Amgen Webcast Investor Call Amgen?will

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

DECEMBER 21, 2020

“The recent results from our NAVIGATOR trial were impressive, both in terms of the overall clinical data and the reduction in exacerbation rate with tezepelumab treatment, and we continue to work with AstraZeneca on planned regulatory filings in 2021. Detailed results from the SOURCE trial will be presented at a future medical meeting.

Trials 40

Trials Production Clinical Trials Therapies 40

The Pharma Data

NOVEMBER 5, 2020

Background and reason Moberg Pharma is a Specialty Pharma company focused on developing and commercialising proprietary, acquired and licensed products globally, from clinical development of products based on proven substances to commercialisation. The following files are available for download: View original content: [link].

Marketing 40

Marketing Production Regulations Pharma Companies 40

Agency IQ

SEPTEMBER 29, 2023

Essential requirements for interoperability of data spaces: The participants of the data space must sufficiently describe (in machine-readable format where applicable) the dataset content, use restrictions, licenses, data collection methodology and quality. app interfaces) automatically and through bulk download where technically feasible.

Regulations 40

Regulations Government Production International 40

The Pharma Data

JANUARY 21, 2021

Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. In the U.S., Read full announcement here: [link].

FDA Approval 52

FDA Approval Treatment RNA FDA 52

The Pharma Data

MAY 14, 2021

Neither ClickBank nor the author are engaged in rendering medical or similar professional services or advice via this website or in the product, and the information provided is not intended to replace medical advice offered by a physician or other licensed healthcare provider. You will get INSTANT ACCESS to download the videos and manuals.

Production 52

Production Licensing Licensing Treatment 52

The Pharma Data

NOVEMBER 15, 2020

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. “Our ambition is to develop life-changing treatments for patients. View original content to download multimedia: [link]. OSS, Netherlands , Nov. About Lead Pharma.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

MAY 13, 2021

The best guidance I ever received was from other women slightly ahead of me in treatment. Once purchased, you will have instant access to download your guide. web site and the ChemoSecrets e-guide regarding treatment, action, or application of the information discussed in this e-guide. I felt LOST.

Production 52

Production Treatment Licensing Licensing 52

PerkinElmer

JUNE 7, 2021

Targeted cancer therapy has been a game changer in cancer treatment, significantly improving the survival and quality of life of many patients. Once we could identify these individual cohorts of patients, we found that each cohort had a different response to treatment, and that patients within the same cohort responded similarly,” he said.

Treatment 52

Treatment Clinical Trials Therapies Trials 52

The Pharma Data

DECEMBER 21, 2020

UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. This progress in clinical development qualifies Ascentage Pharma for a milestone payment according to the terms of the licensing agreement. SUZHOU, China and ROCKVILLE, Md. ,

Clinical Development 40

Clinical Development Disease Treatment Licensing 40

The Pharma Data

OCTOBER 27, 2020

Stargardt disease is a devastating genetic disorder that affects central vision with no approved treatment options. . “This designation permits reVision to further accelerate the development of our Stargardt disease treatment. . View original content to download multimedia: [link].

Disease 40

Disease Treatment FDA Licensing 40

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) has approved WAKIX® (pitolisant) for the treatment of cataplexy in adult patients with narcolepsy. WAKIX is the first and only treatment approved by the FDA for people with excessive daytime sleepiness or cataplexy associated with narcolepsy that is not scheduled as a controlled substance by the U.S.

FDA Approval 40

FDA Approval FDA Treatment Clinical Trials 40

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 131

Therapies Virus DNA Clinical Trials 131

The Pharma Data

JANUARY 17, 2021

plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. SEOUL, South Korea , Jan. U.S. .

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the U.S. STRASBOURG, France and PHILADELPHIA , Jan. This patent family includes one additional U.S.

Treatment 40

Treatment Disease Pharmaceuticals FDA 40